Optipharm Co Ltd
153710
Company Profile
Business description
Optipharm Co Ltd is engaged in developing cell therapy products through animal stem cells, developing high value-added protein drugs using bio-reactors, selecting antibiotic/antiviral components and developing products. Its diagnosis division includes human diagnosis and animal diagnosis that focuses on the development of molecular diagnostics for a variety of diseases.
Contact
6, 63 Osong, Hwaseong-eup
Heungduk-gu
Chungcheongbuk-do
Cheongju
KORT: +82 432497500
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
77
Stocks News & Analysis
stocks
Telstra earnings: No need to get hysterical over mobile
Earnings report in-line with expectations.
stocks
Market Minute: RBA cuts rates again, US CPI data released
This week, the RBA cut rates after a surprise hold in July; CBA reported earnings ; US inflation data came out, showing its highest reading since February.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,233.50 | 21.40 | 0.23% |
| CAC 40 | 7,875.62 | 47.83 | -0.60% |
| DAX 40 | 24,264.05 | 95.25 | -0.39% |
| Dow JONES (US) | 44,946.12 | 34.86 | 0.08% |
| FTSE 100 | 9,139.16 | 0.26 | 0.00% |
| HKSE | 25,176.85 | 93.22 | -0.37% |
| NASDAQ | 21,622.98 | 87.69 | -0.40% |
| Nikkei 225 | 43,714.31 | 336.00 | 0.77% |
| NZX 50 Index | 12,970.64 | 81.26 | 0.63% |
| S&P 500 | 6,449.80 | 18.74 | -0.29% |
| S&P/ASX 200 | 8,959.30 | 20.70 | 0.23% |
| SSE Composite Index | 3,728.03 | 31.26 | 0.85% |